| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 488 | FAB743G | |||
| Allophycocyanin | FAB743A | |||
| Biotin | BAF743 | |||
| Phycoerythrin | FAB743P | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB743A | |||
| Carrier Free | FAB743G | |||
| Carrier Free | FAB743P | |||
| Carrier Free | AF743-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF349-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-18651-0.02mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-43259-0.5mg | |||
| BSA Free | NBP1-43259-0.05mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB743-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB7431-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB349-SP | |||
| Carrier Free | MAB349-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB11624-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB110-61018-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-18653-0.02mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB110-60968-0.025mg | |||
![Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Saphenous vein wall harvested from a patient diagnosed with triple-vessel CAD. Histological sections of a graft wall obtained from a 71-year-old patient who developed early graft failure 11 months after coronary artery bypass grafting. VEGFR-3 (b) is shown to be expressed by immunohistochemical staining in smooth muscle cells of the tunica media (TM) and is strongly present in endothelial cells of the tunica intima (TI). Image collected and cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-9D9-Immunohistochemistry-NBP1-18651-img0011.jpg "Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Saphenous vein wall harvested from a patient diagnosed with triple-vessel CAD. Histological sections of a graft wall obtained from a 71-year-old patient who developed early graft failure 11 months after coronary artery bypass grafting. VEGFR-3 (b) is shown to be expressed by immunohistochemical staining in smooth muscle cells of the tunica media (TM) and is strongly present in endothelial cells of the tunica intima (TI). Image collected and cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9) licensed under a CC-BY license.")
![Western Blot: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Analysis using recombinant human soluble VEGF Receptor 3 as target.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-9D9-Western-Blot-NBP1-18651-img0010.jpg)
![Flow Cytometry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Fig. 1: Flow analysis of VEGFR-3/FLT4 expression in primary human dermal lymphatic endothelial cells (HDLEC).](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-9D9-Flow-Cytometry-NBP1-18651-img0007.jpg)
![Flow Cytometry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Fig. 1: Flow analysis of VEGFR-3/FLT4 expression in primary human dermal mivrovascular endothelial cells (HDMVEC) and human umbilical vein endothelial cells (HUVEC). There is only a very weak expression of VEGFR-3/FLT4 detectable in the HUVECs but a strong one in the HDMVEC.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-9D9-Flow-Cytometry-NBP1-18651-img0006.jpg)
![Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free [NBP1-18651] - Saphenous vein wall harvested from a patient diagnosed with double-vessel CAD showing immunohistochemical staining. VEGF-C (a) & VEGFR-3 (b) reactivity in a graft wall obtained from a 67-year-old patient who developed the early graft restenosis within 7 months after coronary artery bypass grafting (the same patient as mentioned in Fig. 6). VEGF-C is localized exclusively within individual smooth muscle cells of the tunica media (TM). Cells with positive VEGFR-3 expression are situated in endothelial cells of the tunica intima (TI). c Negative control. TA tunica adventitia Image collected & cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-18651_mouse-monoclonal-vegfr3-flt-4-antibody-9d9-310202415363714.jpg)
![Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free [NBP1-18651] - Immunohistochemical staining of an internal thoracic artery & saphenous vein wall harvested from a patient with no evidence of luminal stenosis 12Â months after CABG. Immunohistochemical staining of VEGF-C (a) & CAV2 (b) in an internal thoracic artery (ITA) graft & VEGFR-3 (c) in saphenous vein (SV) transplant harvested from a 65-year-old patient diagnosed with triple-vessel CAD. Note that lack of CAV2 expression within smooth muscle cells (SMC) in ITA wall is accompanied by VEGF-C positive expression in the same area. In SV tissue sample harvested from the same patient, no VEGRR-3 expression was found. d Negative control. TI tunica intima, TM tunica media, TA tunica adventitia Image collected & cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-18651_mouse-monoclonal-vegfr3-flt-4-antibody-9d9-310202415394521.jpg)
![Immunohistochemistry-Frozen: VEGFR3/Flt-4 Antibody (AFL4) [NBP1-43259] - VEGFR-3 (green) was detected in murine cancer using VEGFR-3-AlexaFluor488 antibody (1:50; 1 hour) in PBS. Nuclei were stained with DAPI (blue). Tissue was fixed in acetone. Image from a verified customer review using the Alexa Fluor488 version of this VEGFR-3 antibody.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-AFL4-Immunohistochemistry-Frozen-NBP1-43259-img0003.jpg "Immunohistochemistry-Frozen: VEGFR3/Flt-4 Antibody (AFL4) [NBP1-43259] - VEGFR-3 (green) was detected in murine cancer using VEGFR-3-AlexaFluor488 antibody (1:50; 1 hour) in PBS. Nuclei were stained with DAPI (blue). Tissue was fixed in acetone. Image from a verified customer review using the Alexa Fluor488 version of this VEGFR-3 antibody.")
![Flow Cytometry: VEGFR3/Flt-4 Antibody (AFL4) [NBP1-43259] - Surface staining of MC/9 cell line with Anti-Mouse Fc epsilon Receptor I alpha (Fc epsilon R1) FITC (left) and PE (right). Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-AFL4-Flow-Cytometry-NBP1-43259-img0002.jpg)
![Immunohistochemistry-Paraffin: VEGF Receptor 3 Antibody (RM0003-5F63) [NB110-61018] - 4% PFA fixed mouse heart and kidney tissue sections were subjected to IHC with rat anti mouse VEGFR3 (RM0003-5F63).](http://images.novusbio.com/fullsize/VEGF-Receptor-3-Antibody-RM0003-5F63-Immunohistochemistry-Paraffin-NB110-61018-img0001.jpg "Immunohistochemistry-Paraffin: VEGF Receptor 3 Antibody (RM0003-5F63) [NB110-61018] - 4% PFA fixed mouse heart and kidney tissue sections were subjected to IHC with rat anti mouse VEGFR3 (RM0003-5F63).")
![Western Blot: VEGFR3/Flt-4 Antibody (7A3) [NBP1-18653] - Analysis with VEGFR-3/FLT-4 expressing PAEC endothelial cells.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-7A3-Western-Blot-NBP1-18653-img0005.jpg "Western Blot: VEGFR3/Flt-4 Antibody (7A3) [NBP1-18653] - Analysis with VEGFR-3/FLT-4 expressing PAEC endothelial cells.")
![Immunocytochemistry/Immunofluorescence: VEGFR3/Flt-4 Antibody (7A3) [NBP1-18653] - Staining (green) of VEGFR-3/FLT-4 in primary mouse endothelial cells with anti-mouse VEGFR-3/FLT-4 #7A3 (10ug/ml) and counter staining of nuclei with Dapi. As secondary antibody goat anti-mouse ALEXA Flour 488 (Dianova) was used 1:400.](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-7A3-Immunocytochemistry-Immunofluorescence-NBP1-18653-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: VEGFR3/Flt-4 Antibody (7A3) [NBP1-18653] - Immunofluorescence staining of VEGFR-3/FLT4 in mouse primary endothelial cells (SnoMec) with monoclonal rat anti-mouse VEGFR-3/FLT4 #7A3 (upper panel). Control with goat anti-rat ALEXA Flour 488 [Dianova] (lower panel).](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-7A3-Immunocytochemistry-Immunofluorescence-NBP1-18653-img0004.jpg)
![Western Blot: VEGFR3/Flt-4 Antibody (MM0003-7G63) - Azide and BSA Free [NB110-60968] - Lysate of human placenta tissue with Mouse Monoclonal anti-Human VEGFR3](http://images.novusbio.com/fullsize/VEGFR3-Flt-4-Antibody-MM0003-7G63-Azide-and-BSA-Free-Western-Blot-NB110-60968-img0003.jpg "Western Blot: VEGFR3/Flt-4 Antibody (MM0003-7G63) - Azide and BSA Free [NB110-60968] - Lysate of human placenta tissue with Mouse Monoclonal anti-Human VEGFR3")
![Immunohistochemistry-Paraffin: VEGF R3/Flt-4 Antibody (MM0003-7G63) [NB110-60968] - Formalin Fixed and Paraffin embedded human placenta tissue section (Proteinase K pretreatment is required).](http://images.novusbio.com/fullsize/VEGF-R3-Flt-4-Antibody-MM0003-7G63-Immunohistochemistry-Paraffin-NB110-60968-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: VEGF R3/Flt-4 Antibody [NBP2-68669] - Staining of human cell line MCF7 shows localization to nucleoplasm & plasma membrane.](http://images.novusbio.com/fullsize/VEGF-R3-Flt-4-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-68669-img0001.jpg "Immunocytochemistry/Immunofluorescence: VEGF R3/Flt-4 Antibody [NBP2-68669] - Staining of human cell line MCF7 shows localization to nucleoplasm & plasma membrane.")